People: Biodel Inc (BIOD.PH)
BIOD.PH on Philadelphia Stock Exchange
2.90USD
25 Apr 2013
2.90USD
25 Apr 2013
Price Change (% chg)
$0.00 (+0.00%)
$0.00 (+0.00%)
Prev Close
$2.90
$2.90
Open
$2.90
$2.90
Day's High
$2.90
$2.90
Day's Low
$2.90
$2.90
Volume
300
300
Avg. Vol
--
--
52-wk High
--
--
52-wk Low
--
--
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Ira Lieberman |
70 | 2013 | Independent Chairman of the Board |
Errol De Souza |
59 | 2010 | President, Chief Executive Officer, Director |
Gerard Michel |
49 | 2007 | Chief Financial Officer, Vice President - Corporate Development, Treasurer |
Erik Steiner |
47 | 2003 | Vice President - Operations |
Paul Bavier |
40 | 2008 | General Counsel, Secretary |
Alan Krasner |
49 | 2008 | Chief Medical Officer |
Davey Scoon |
66 | 2012 | Director |
Julia Brown |
66 | 2012 | Independent Director |
Barry Ginsberg |
67 | 2008 | Independent Director |
Daniel Lorber |
65 | 2004 | Independent Director |
Brian Pereira |
54 | 2013 | Independent Director |
Biographies
| Name | Description |
|---|---|
Ira Lieberman |
Dr. Ira W. Lieberman, Ph.D., is Independent Chairman of the Board of Biodel Inc. She has served as Independent Director from 2004 to 2013. Since October 2004, Dr. Lieberman has served as President and Chief Executive Officer of LIPAM International, Inc., an advisory and investment firm, which performs advisory and consulting work for the World Bank, client governments, and private sector clients. From July 2003 to October 2004, Dr. Lieberman served as a Senior Economic Advisor to George Soros for the Open Society Institute, a grant making foundation. From February 1993 to July 2004, Dr. Lieberman served in several positions for the World Bank. Dr. Lieberman received an MBA from Columbia University and a Ph.D. from Oxford University. |
Errol De Souza |
Dr. Errol B. De Souza, Ph.D., is President, Chief Executive Officer, Director of Biodel Inc. Dr. De Souza joined management and board of directors in March 2010. Dr. De Souza has over two decades of experience in the biopharmaceutical industry. From March 2009 until March 2010, Dr. De Souza was a pharmaceutical and biotechnology consultant. From April 2003 to January 2009, Dr. De Souza was president and chief executive officer of Archemix Corporation, a privately.held biopharmaceutical company focused on aptamer therapeutics. From September 2002 to March 2003, he was president, chief executive officer and a director of Synaptic Pharmaceuticals Corporation, a publicly traded biopharmaceutical company that was acquired by H. Lundbeck A/S in March 2003. Dr. De Souza is a member of the board of directors of each of the following publicly traded companies: Bionomics Ltd. and Targacept, Inc. Dr. De Souza received his B.A. (Honors) in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine. |
Gerard Michel |
Mr. Gerard J. Michel is Chief Financial Officer, Vice President - Corporate Development, Treasurer of Biodel Inc. From October 2003 to November 2007, Mr. Michel served as Chief Financial Officer and from April 2006 to November 2007, Vice President, Corporate Development of NPS Pharmaceuticals, a publicly traded biopharmaceutical company. From June 1995 to July 2002, Mr. Michel served as a Principal of the consulting firm Booz-Allen & Hamilton. From 1988 to 1995, Mr. Michel held various licensing, sales and product management roles at Lederele Labs and Wyeth. Mr. Michel received an MBA and B.S. from The University of Rochester, and an M.S., in Microbiology from The University of Rochester School of Medicine and Dentistry. |
Erik Steiner |
Mr. Erik Steiner is Vice President - Operations of Biodel Inc. He co-founded company and has served as Vice President, Operations since company's inception in December 2003. From February 2003 to December 2003, Mr. Steiner co-founded and served as the Vice President, Operations of Steiner Ventures. From May 1999 to February 2003, Mr. Steiner served as Head of Operations of Cabot McMullen Inc., a film and television production company. Prior thereto, Mr. Steiner served as Administrative Director and Fiscal Administrator of the New Jersey Public Interest Research Group. |
Paul Bavier |
Mr. Paul S. Bavier is General Counsel, Secretary of Biodel Inc. From October 2007 to December 2008, Mr. Bavier served as the Deputy General Counsel. From November 2004 to October 2007, Mr. Bavier served as Assistant General Counsel at Gerber Scientific, Inc. Mr. Bavier began his legal career as an associate in the corporate law department of Ropes & Gray LLP in Boston. He holds a B.A. from Middlebury College and a J. D. from the University of Michigan Law School. |
Alan Krasner |
Dr. Alan Seth Krasner, M.D., is Chief Medical Officer of Biodel Inc. From 2002 to 2008, Dr. Krasner served as Director in the Department of Clinical Research Metabolic Diseases at Pfizer Global Research and Development where he was responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates. Dr. Krasner currently serves as a consulting physician at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial Hospital in New London, Connecticut. Dr. Krasner holds a B.S. from the Medical Education Honors Program at Northwestern University and an M.D. from Northwestern University Medical School. He completed his residency at Johns Hopkins Hospital in internal medicine and subsequently completed his fellowship at Johns Hopkins Hospital in endocrinology and metabolism. |
Davey Scoon |
Mr. Davey S. Scoon is Director of Biodel Inc. His business career has included senior executive positions in Finance and Administration across a range of industries including asset management, insurance, retailing and consumer products. His board leadership positions include board chair and audit chair positions in industries including mutual funds, health insurance and life sciences. Mr. Scoon is currently the non-executive Chairman of Tufts Health Plan, Chair of the board of trustees for Allianz Global Investors and a board member and Audit Chair of AMAG Pharmaceuticals, Inc. and Orthofix International N.V. Previously he served as the Chairman of the audit committees of NitroMed, Inc. and CardioKine, Inc. In addition to his board work, Mr. Scoon is an adjunct professor teaching accounting at the University of Wisconsin-Madison. Mr. Scoon’s previous corporate experience includes Chief Administrative and Financial Officer of Tom’s of Maine, Inc., Chief Administrative and Financial Officer of Sunlife Financial U.S., Executive Vice President and Chief Operating Officer of Liberty Funds Group of Boston (formerly Colonial Management) and Certified Public Accountant with Price Waterhouse & Company. Mr. Davey earned an MBA from Harvard Business School and a BBA in Business Administration from the University of Wisconsin. |
Julia Brown |
Ms. Julia R. Brown Independent Director of Biodel Inc. She has held a variety of executive positions over her 40 year career in the pharmaceutical industry. From 2000-2003, Ms. Brown was Executive Vice President of Amylin Pharmaceuticals, Inc., responsible for commercial operations. She served as Advisor to the CEO until 2008. Prior to joining Amylin, Ms. Brown was Executive Vice President of Dura Pharmaceuticals, Inc. Ms. Brown spent over 25 years with Eli Lilly and Company in progressively more senior roles including Vice President of IVAC Corporation and General Manager of its Vital Signs Division and Vice President of Worldwide Marketing for Hybritech. Ms. Brown is currently a member of the board of directors of Targacept, Inc. and serves as chair of its compensation committee. She has previously served on the board of directors of several other development stage pharmaceutical or biopharmaceutical companies. She is a member of the National Association of Corporate Directors, Women Corporate Directors and is a member of the board of Corporate Directors Forum—all organizations which are dedicated to high standards of professionalism in corporate governance. Ms. Brown chairs the board of trustees of the UC San Diego Foundation. She is a member of the board of CONNECT, an organization that fosters innovation, entrepreneurship and the formation of new companies in southern California. Ms. Brown is a graduate of Louisiana Tech University where she studied microbiology and biochemistry. |
Barry Ginsberg |
Dr. Barry Ginsberg, M.D., Ph.D., is Independent Director of Biodel Inc. Dr. Ginsberg currently serves as Chief Executive Officer of Diabetes Technology Consultants and holds over 25 years of experience in diabetes. Prior to Diabetes Technology Consultants, Dr. Ginsberg served as Vice President of Worldwide Medical Affairs in the Diabetes HealthCare Division at Becton Dickinson during his 17 year tenure. Dr. Ginsberg currently serves as Chairman of the Scientific Advisory Boards at Agamatrix and D-Medical Industries, Ltd. Dr. Ginsberg received both an M.D. and Ph.D. in Molecular Biology from Albert Einstein College of Medicine, was a Professor of Medicine and Biochemistry at the University of Iowa and Principal Investigator of the Diabetes Control and Complications Trial. |
Daniel Lorber |
Dr. Daniel Lorber is Independent Directorof Biodel Inc. Since October 2004, he is a member of company's scientific advisory board. Since 1981, Dr. Lorber has served as the medical director of the Diabetes Control Foundation, Diabetes Care and Information Center in Flushing, New York and since 1991, as the director of endocrinology at The New York Hospital Medical Center of Queens. Dr. Lorber is also an attending physician in endocrinology and general internal medicine and Associate Director of the Lang Center for Research and Education at the New York Hospital Medical Center of Queens. Since 1994, Dr. Lorber has served as a clinical associate professor of medicine at Weill Medical College of Cornell University. Dr. Lorber also serves as a consultant in medical, dental and podiatric liability litigation and to the insurance industry on care standards for diabetes mellitus. Dr. Lorber is a past member of the board of directors of the American Diabetes Association and President of the ADA Long Island leadership council. Dr. Lorber received an M.D. from the Albert Einstein College of Medicine and completed a fellowship in endocrinology at the Vanderbilt University Medical Center. |
Brian Pereira |
Dr. Brian J.G. Pereira, M.D., is Independent Director of the Board of Biodel Inc. He has served as Independent Chairman of the Board. Dr. Pereira joined AMAG Pharmaceuticals, Inc., a biopharmaceutical company, as President in November 2005, and he was appointed Chief Executive Officer in November 2006, serving in that capacity until November 2011. Prior to joining AMAG Pharmaceuticals, Dr. Pereira was President and Chief Executive Officer of the New England Health Care Foundation, a physician’s group at Tufts-New England Medical Center from October 2001 to November 2005, and he held various other positions at Tufts-New England Medical Center from 1993 to 2001. From 2002 to 2004, Dr. Pereira served as President of the National Kidney Foundation, and he has served on the editorial board of twelve scientific journals. He is Adjunct Professor of Medicine at Tufts University School of Medicine and at the Sackler School of Biomedical Sciences of Tufts University. He currently serves on the Board of Directors of the American India Foundation. Dr. Pereira is a graduate of St. John’s Medical College, Bangalore, India and has an MBA from the Kellogg Business School, Northwestern University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Ira Lieberman |
-- |
Errol De Souza |
695,282 |
Gerard Michel |
430,561 |
Erik Steiner |
312,627 |
Paul Bavier |
385,749 |
Alan Krasner |
423,127 |
Davey Scoon |
-- |
Julia Brown |
-- |
Barry Ginsberg |
-- |
Daniel Lorber |
-- |
Brian Pereira |
-- |
As Of 29 Sep 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Ira Lieberman |
0 | 0 |
Errol De Souza |
0 | 0 |
Gerard Michel |
0 | 0 |
Erik Steiner |
0 | 0 |
Paul Bavier |
0 | 0 |
Alan Krasner |
0 | 0 |
Davey Scoon |
0 | 0 |
Julia Brown |
0 | 0 |
Barry Ginsberg |
0 | 0 |
Daniel Lorber |
0 | 0 |
Brian Pereira |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
MICHEL GERARD J |
1,883 | $0.00 |
MICHEL GERARD J |
5,712 | $0.00 |
KRASNER ALAN SETH |
1,854 | $0.00 |
KRASNER ALAN SETH |
6,024 | $0.00 |
BAVIER PAUL S |
4,799 | $0.00 |
STEINER ERIK |
480 | $0.00 |
DE SOUZA ERROL B |
5,625 | $0.00 |
BAVIER PAUL S |
1,497 | $0.00 |
BAVIER PAUL S |
12,256 | $2.80 |
KRASNER ALAN SETH |
1,100 | $2.78 |
KRASNER ALAN SETH |
2,400 | $2.82 |
MICHEL GERARD J |
28,964 | $0.00 |
MICHEL GERARD J |
12,205 | $2.87 |
DE SOUZA ERROL B |
56,250 | $0.00 |
KRASNER ALAN SETH |
27,296 | $0.00 |
DE SOUZA ERROL B |
56,250 | $0.00 |
KRASNER ALAN SETH |
8,323 | $2.87 |
STEINER ERIK |
17,899 | $0.00 |
STEINER ERIK |
6,411 | $2.87 |
DE SOUZA ERROL B |
18,973 | $2.87 |
BAVIER PAUL S |
18,640 | $0.00 |
BAVIER PAUL S |
6,832 | $2.87 |
DE SOUZA ERROL B |
18,973 | $2.87 |
BAVIER PAUL S |
8,385 | $0.59 |
DE SOUZA ERROL B |
1,784 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
